Followers | 234 |
Posts | 26887 |
Boards Moderated | 0 |
Alias Born | 01/12/2013 |
![](https://investorshub.advfn.com/uicon/377108.png?cb=1701103334)
Tuesday, August 18, 2020 6:37:06 PM
I have no comment until 29th, Docket speaks for me.
Court of Appeals Docket #: 20-2108 Docketed: 08/03/2020
Nature of Suit: 835 Patent - (ANDA) (Fed. Question)
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc
Appeal From: United States District Court for the District of Nevada
Fee Status: fee paid
Case Type Information:
1) Civil Private
2) -
3) -
Originating Court Information:
District: 0978-3 : 3:20-cv-00421-MMD-CLB
Trial Judge: Miranda M. Du, Judge
Date Filed: 07/13/2020
Date NOA Filed: Date Rec'd COA:
07/27/2020 07/27/2020
08/06/2020 2 Entry of appearance for Jonathan E. Singer; Deanna J. Reichel; Nitika Gupta Fiorella; Oliver Richards; Eric Sonnenschein; Jeffrey Elikan; Christopher Sipes as counsel for Appellants Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited. Service: 08/06/2020 by email. [713105] [20-2108] [Jonathan Singer] [Entered: 08/06/2020 03:20 PM]
08/06/2020 3 Certificate of Interest for Appellants Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited. Service: 08/06/2020 by email. [713107] [20-2108] [Jonathan Singer] [Entered: 08/06/2020 03:23 PM]
08/06/2020 4 Docketing Statement for the Appellants Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited. Service: 08/06/2020 by email. [713111] [20-2108] [Jonathan Singer] [Entered: 08/06/2020 03:25 PM]
08/06/2020 5 Entry of appearance for Charles B. Klein; Eimeric Reig-Plessis; Claire A. Fundakowski; Alison M. Heydorn as counsel for Appellees Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals International Limited. Service: 08/06/2020 by email. [713140] [20-2108] [Charles Klein] [Entered: 08/06/2020 04:23 PM]
08/06/2020 6 Docketing Statement for the Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc.. Service: 08/06/2020 by email. [713145] [20-2108] [Charles Klein] [Entered: 08/06/2020 04:28 PM]
08/06/2020 7 Certificate of Interest for Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc.. Service: 08/06/2020 by email. [713146] [20-2108] [Charles Klein] [Entered: 08/06/2020 04:31 PM]
08/11/2020 8 MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to consolidate appeals (20-1723) [Consent: unopposed]. Service: 08/11/2020 by email. [714224] [20-2108] This document is non-compliant. See Doc No. [9] [Deanna Reichel] [Entered: 08/11/2020 02:53 PM]
08/12/2020 9 NOTICE OF NON-COMPLIANCE: The submission of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc., Motion to consolidate appeals [8], is not in compliance with the rules of this court (see attached). Compliant document due on 08/19/2020. Service as of this date by the Clerk of Court. [714370] [KMH] [Entered: 08/12/2020 10:11 AM]
08/12/2020 10 MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to consolidate appeals (20-1723) [Consent: unopposed]. Service: 08/12/2020 by email. [714411] [20-2108] [Deanna Reichel] [Entered: 08/12/2020 12:39 PM]
08/12/2020 11 MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to consolidate appeals (20-1723) [Consent: unopposed]. Service: 08/12/2020 by email. [714414] [20-2108] [Deanna Reichel] [Entered: 08/12/2020 12:49 PM]
If you're not good at being yourself, then maybe that's being yourself!
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM